These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 17907057)
1. Genetic variation of estrogen metabolism and the risks of cardiovascular disease. Almeida S; Hutz MH Curr Opin Investig Drugs; 2007 Oct; 8(10):814-20. PubMed ID: 17907057 [TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Kjaergaard AD; Ellervik C; Tybjaerg-Hansen A; Axelsson CK; Grønholdt ML; Grande P; Jensen GB; Nordestgaard BG Circulation; 2007 Feb; 115(7):861-71. PubMed ID: 17309937 [TBL] [Abstract][Full Text] [Related]
3. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952 [TBL] [Abstract][Full Text] [Related]
4. The association between the rs2234693 and rs9340799 estrogen receptor alpha gene polymorphisms and risk factors for cardiovascular disease: a review. Casazza K; Page GP; Fernandez JR Biol Res Nurs; 2010 Jul; 12(1):84-97. PubMed ID: 20702456 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of hormone replacement therapy for climacteric symptoms. Takeo C; Ugai K; Araki J; Zhang L; Baba M; Ohashi W; Ueno K; Suzuki Y; Amano K; Hirai A; Muramatsu M Biochem Biophys Res Commun; 2008 Oct; 374(4):604-8. PubMed ID: 18627768 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of ESR1 and ESR2 that may influence estrogen activity and the risk of hypospadias. Ban S; Sata F; Kurahashi N; Kasai S; Moriya K; Kakizaki H; Nonomura K; Kishi R Hum Reprod; 2008 Jun; 23(6):1466-71. PubMed ID: 18375409 [TBL] [Abstract][Full Text] [Related]
7. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Koledova VV; Khalil RA Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655 [TBL] [Abstract][Full Text] [Related]
8. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Dubey RK; Imthurn B; Barton M; Jackson EK Cardiovasc Res; 2005 May; 66(2):295-306. PubMed ID: 15820198 [TBL] [Abstract][Full Text] [Related]
9. ER-alpha variants and the cardiovascular effects of hormone replacement therapy. Herrington DM; Howard TD Pharmacogenomics; 2003 May; 4(3):269-77. PubMed ID: 12718718 [TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Gennari L; Merlotti D; De Paola V; Calabrò A; Becherini L; Martini G; Nuti R Am J Epidemiol; 2005 Feb; 161(4):307-20. PubMed ID: 15692074 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage. Cupisti S; Fasching PA; Ekici AB; Strissel PL; Loehberg CR; Strick R; Engel J; Dittrich R; Beckmann MW; Goecke TW Arch Gynecol Obstet; 2009 Sep; 280(3):395-400. PubMed ID: 19152063 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. Bakas P; Liapis A; Vlahopoulos S; Giner M; Logotheti S; Creatsas G; Meligova AK; Alexis MN; Zoumpourlis V Fertil Steril; 2008 Nov; 90(5):1878-85. PubMed ID: 18166184 [TBL] [Abstract][Full Text] [Related]
13. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. Schwartz AG; Wenzlaff AS; Prysak GM; Murphy V; Cote ML; Brooks SC; Skafar DF; Lonardo F J Clin Oncol; 2007 Dec; 25(36):5785-92. PubMed ID: 18089876 [TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease. Yende S; Wunderink RG Curr Opin Crit Care; 2006 Oct; 12(5):420-5. PubMed ID: 16943719 [TBL] [Abstract][Full Text] [Related]
15. Estrogen and its receptors in cancer. Chen GG; Zeng Q; Tse GM Med Res Rev; 2008 Nov; 28(6):954-74. PubMed ID: 18642351 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Chan KK; Wei N; Liu SS; Xiao-Yun L; Cheung AN; Ngan HY Obstet Gynecol; 2008 Jan; 111(1):144-51. PubMed ID: 18165403 [TBL] [Abstract][Full Text] [Related]
17. Nutrigenetics and CVD: what does the future hold? Lovegrove JA; Gitau R Proc Nutr Soc; 2008 May; 67(2):206-13. PubMed ID: 18412994 [TBL] [Abstract][Full Text] [Related]
18. [Hormone replacement therapy and cardiovascular risk in postmenopausal women]. Kovacev-Zavisić B; Icin T; Kovacev N Med Pregl; 2009; 62 Suppl 3():85-90. PubMed ID: 19702123 [TBL] [Abstract][Full Text] [Related]
19. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Yang XR; Pfeiffer RM; Garcia-Closas M; Rimm DL; Lissowska J; Brinton LA; Peplonska B; Hewitt SM; Cartun RW; Mandich D; Sasano H; Evans DB; Sutter TR; Sherman ME Cancer Res; 2007 Nov; 67(21):10608-17. PubMed ID: 17968031 [TBL] [Abstract][Full Text] [Related]
20. [Hormone replacement Up-to-date. Effects of estrogen replacement therapy on lipid metabolism]. Wakatsuki A Clin Calcium; 2007 Sep; 17(9):1366-71. PubMed ID: 17767025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]